OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Forsyth on the Investigation of Intrathecal Dendritic Cells for HER2+/TNBC Leptomeningeal Disease

June 11th 2024

Peter Forsyth, MD, discusses a study of intrathecal dendritic cells in patients with leptomeningeal disease from TNBC or HER2-positive breast cancer.

Dr Bellmunt on Predictive Signatures for Checkpoint Inhibitor Responses in Urothelial Cancer

June 11th 2024

Joaquim Bellmunt, MD, PhD, discusses the predictive value of H3K27ac epigenomic and single-cell transcriptional profiling in urothelial cancer.

Dr Huffman on the Investigation of Azenosertib Plus Gemcitabine in Advanced Pancreatic Cancer

June 11th 2024

Brandon Huffman, MD, discusses an ongoing phase 2 trial evaluating azenosertib plus gemcitabine in advanced pancreatic cancer.

Dr Neelapu on Clinical Trial Data With CAR T-Cell Therapy in Lymphoma

June 11th 2024

Sattva S. Neelapu, MD, discusses key clinical trial data that support the use of CAR T-cell therapy in standard practice for patients with lymphoma.

Dr Vose on the Investigation of Epcoritamab in Relapsed/Refractory Follicular Lymphoma

June 11th 2024

Julie M. Vose, MD, MBA, discusses the investigation of epcoritamab in relapsed/refractory follicular lymphoma.

Dr Nayak on the Investigation of Axi-Cel in CNS Lymphoma

June 11th 2024

Lakshmi Nayak, MD, discusses the investigation of axi-cel in patients with relapsed/refractory primary and secondary CNS lymphoma.

Dr Burke on Ongoing Investigations in Lymphoma Treatment

June 11th 2024

John M. Burke, MD discussed ongoing investigations into the treatment of lymphoma that were presented at ASCO 2024.

Dr Manich on the ReDiscover Study of RLY-2608 in PIK3CA-Mutant Advanced Solid Tumors

June 11th 2024

Cristina Saura Manich, MD, PhD, discusses the phase 1 ReDiscover study evaluating RLY-2608 in patients with PIK3CA-mutated advanced breast cancer and other solid tumors.

Dr Watts on the Safety of the BET Inhibitor INCB057643 in Myelofibrosis

June 11th 2024

Justin M. Watts, MD, discusses the safety profile and tolerability of INCB057643 in patients with myelofibrosis.

Dr Garje on the Prognostic Value of HPV Status for Survival Outcomes in pSCC

June 10th 2024

Rohan Garje, MD, discusses the impact of human papillomavirus status on survival outcomes in penile squamous cell carcinoma.

Dr Cecchini on the Initial Efficacy of CM24 Plus Nivolumab and NALIRIFOX in Advanced PDAC

June 10th 2024

Michael Cecchini, MD, discusses interim data on the use of CM24 with nivolumab and NALIRIFOX in advanced/metastatic pancreatic ductal adenocarcinoma.

Dr Ahluwalia on the Incidence of Brain Metastases in RCC

June 10th 2024

Manmeet Ahluwalia, MD, MBA, FASCO, discusses findings from a National Cancer Database analysis on treatment outcomes of brain metastases from primary RCC.

Dr Svoboda on the Efficacy of Armored huCART19-IL18 in R/R Lymphoma

June 10th 2024

Jakub Svoboda, MD, discusses outcomes with armored huCART19-IL18 in patients with previously treated relapsed/refractory lymphomas that have progressed.

Dr Kamath on the Tumor Microbiome of Early- and Average-Onset PDAC

June 10th 2024

Suneel Kamath, MD, discusses tumor microbiome differences between early-onset and average-onset pancreatic adenocarcinoma.

Dr Mehra on Transoral Surgery and Risk-Based Radiation in HPV+ Oropharynx Cancer

June 10th 2024

Ranee Mehra, MD, discusses long-term results for primary transoral surgery followed by reduced postoperative radiation in HPV-associated oropharynx cancer.

Dr Strosberg on 212Pb-DOTAMTATE in Unresectable/Metastatic SSTR+ GEP-NETs

June 10th 2024

Jonathan Strosberg, MD, discusses safety data for 212Pb-DOTAMTATE in metastatic somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors.

Dr Gadi on Results From of the DESTINY-Breast06 Trial in HR+/HER2-Low Breast Cancer

June 7th 2024

VK Gadi, MD, PhD, discusses primary results from the phase 3 DESTINY-Breast06 trial of trastuzumab deruxtecan in HR-positive, HER2-low breast cancer.

Dr Jhaveri on the Implications of Treatment With RLY-2608 in Advanced ER+ Breast Cancer

June 7th 2024

Komal Jhaveri, MD, FACP, discusses the implications of investigating treatment with RLY-2608 in patients with PIK3CA-mutant advanced ER+ breast cancer.

Dr Pegram on the Implications and Safety of T-DXd in HR+/HER2-Low and -Ultralow Breast Cancer

June 7th 2024

Mark Pegram, MD, discusses implications of and safety data from the primary analysis of the DESTINY-Breast06 trial in HR+/HER2– metastatic breast cancer.

Dr Spigel on the Efficacy of Durvalumab Consolidation Therapy in LS-SCLC

June 7th 2024

David R. Spigel, MD, discusses findings from the phase 3 ADRIATIC trial in patients with limited-stage small cell lung cancer.